Risk of Post-COVID Conditions among adolescents and adults who received nirmatrelvir-ritonavir for acute COVID-19: a retrospective cohort study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective cohort study reveals nirmatrelvir-ritonavir reduces post-covid conditions in older adults, suggesting potential outpatient benefits.

Nirmatrelvir-ritonavir treatment significantly reduces post-covid conditions risk in adults aged 50-64 years and ≥65 years.
In the study, treated patients had a reduced risk of developing post-covid conditions (aHR 0.93) compared to matched untreated patients.
A retrospective cohort study utilized real-world claims data to analyze the effects of nirmatrelvir-ritonavir treatment on post-covid conditions.
These findings support the consideration of nirmatrelvir-ritonavir for treating mild to moderate COVID-19 to mitigate severe outcomes.

Dalton et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective cohort study reveals nirmatrelvir-ritonavir reduces post-covid conditions in older adults, suggesting potential outpatient benefits.